BR0306838A - Peptìdeo não-nativo, ácido nucléico isolado, composição farmacêutica e kit para prevenção ou tratamento de uma doença modulada por crf2r - Google Patents

Peptìdeo não-nativo, ácido nucléico isolado, composição farmacêutica e kit para prevenção ou tratamento de uma doença modulada por crf2r

Info

Publication number
BR0306838A
BR0306838A BR0306838-2A BR0306838A BR0306838A BR 0306838 A BR0306838 A BR 0306838A BR 0306838 A BR0306838 A BR 0306838A BR 0306838 A BR0306838 A BR 0306838A
Authority
BR
Brazil
Prior art keywords
treatment
kit
prevention
nucleic acid
pharmaceutical composition
Prior art date
Application number
BR0306838-2A
Other languages
English (en)
Inventor
Robert Joseph Isfort
Wieslaw Adam Mazur
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of BR0306838A publication Critical patent/BR0306838A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57509—Corticotropin releasing factor [CRF] (Urotensin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"PEPTìDEO NãO-NATIVO, áCIDO NUCLéICO ISOLADO, COMPOSIçãO FARMACêUTICA E KIT PARA PREVENçãO OU TRATAMENTO DE UMA DOENçA MODULADA POR CRF~ 2~R". A presente invenção refere-se a derivados isolados de fator de liberação de corticotropina, bem como os ácidos nucléicos que os codificam, que são eficazes para o tratamento de distúrbios modulados pelo receptor do fator de liberação de corticotropina 2, como a distrofia muscular.
BR0306838-2A 2002-01-16 2003-01-16 Peptìdeo não-nativo, ácido nucléico isolado, composição farmacêutica e kit para prevenção ou tratamento de uma doença modulada por crf2r BR0306838A (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US34911702P 2002-01-16 2002-01-16
US37633702P 2002-04-29 2002-04-29
US38889502P 2002-06-14 2002-06-14
US41198802P 2002-09-19 2002-09-19
PCT/US2003/001461 WO2003062269A2 (en) 2002-01-16 2003-01-16 Corticotropin releasing factor receptor 2 agonists

Publications (1)

Publication Number Publication Date
BR0306838A true BR0306838A (pt) 2005-04-05

Family

ID=27617822

Family Applications (3)

Application Number Title Priority Date Filing Date
BR0306878-1A BR0306878A (pt) 2002-01-16 2003-01-16 Peptìdeo não-agonista do receptor de fator de liberação de corticotropina 2, ácido nucleico e anticorpo isolados, composição farmacêutica e kit compreendendo o referido peptìdeo e uso do referido peptìdeo e ácido nucleico na fabricação de um medicamento
BR0306826-9A BR0306826A (pt) 2002-01-16 2003-01-16 Peptìdeo não-nativo, ácido nucléico isolado, anticorpo isolado, composição farmacêutica e kit para prevenção e tratamento de uma doença modulada por crf2r
BR0306838-2A BR0306838A (pt) 2002-01-16 2003-01-16 Peptìdeo não-nativo, ácido nucléico isolado, composição farmacêutica e kit para prevenção ou tratamento de uma doença modulada por crf2r

Family Applications Before (2)

Application Number Title Priority Date Filing Date
BR0306878-1A BR0306878A (pt) 2002-01-16 2003-01-16 Peptìdeo não-agonista do receptor de fator de liberação de corticotropina 2, ácido nucleico e anticorpo isolados, composição farmacêutica e kit compreendendo o referido peptìdeo e uso do referido peptìdeo e ácido nucleico na fabricação de um medicamento
BR0306826-9A BR0306826A (pt) 2002-01-16 2003-01-16 Peptìdeo não-nativo, ácido nucléico isolado, anticorpo isolado, composição farmacêutica e kit para prevenção e tratamento de uma doença modulada por crf2r

Country Status (30)

Country Link
US (7) US7192924B2 (pt)
EP (4) EP1724283B1 (pt)
JP (3) JP4508648B2 (pt)
KR (3) KR100758858B1 (pt)
CN (3) CN100475844C (pt)
AR (3) AR038143A1 (pt)
AT (4) ATE398632T1 (pt)
AU (2) AU2003205197B2 (pt)
BR (3) BR0306878A (pt)
CA (3) CA2470743C (pt)
CY (1) CY1106133T1 (pt)
DE (4) DE60318547T2 (pt)
DK (2) DK1465921T3 (pt)
ES (4) ES2309909T3 (pt)
HK (1) HK1078095A1 (pt)
IL (5) IL162431A0 (pt)
MA (3) MA27590A1 (pt)
MX (3) MXPA04006885A (pt)
MY (1) MY140306A (pt)
NO (3) NO20043366L (pt)
NZ (3) NZ533599A (pt)
PE (3) PE20030849A1 (pt)
PL (3) PL373529A1 (pt)
PT (2) PT1465921E (pt)
RU (1) RU2294333C2 (pt)
SA (3) SA03230565B1 (pt)
SI (1) SI1465921T1 (pt)
TW (3) TW200302278A (pt)
WO (3) WO2003062269A2 (pt)
ZA (1) ZA200404995B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2427490A1 (en) * 2000-09-22 2002-03-28 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Methods for improving the antagonistic/agonistic properties of peptidic antagonists/agonists of the corticotropin-releasing factor receptor (crfr)
US7192924B2 (en) * 2002-01-16 2007-03-20 The Procter & Gamble Company Corticotropin releasing factor 2 receptor agonists
WO2005103690A2 (en) * 2004-04-24 2005-11-03 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with corticotropin releasing hormone receptor 2 (crhr2)
MX2007012057A (es) * 2005-03-30 2007-11-23 Novartis Vaccines & Diagnostic Haemophilus influenzae tipo b.
WO2007090087A2 (en) * 2006-01-27 2007-08-09 Research Development Foundation Use of corticotropin releasing factor receptor-2 inhibitors for treating insulin-related diseases
US20100184674A1 (en) * 2007-09-11 2010-07-22 Dorian Bevec Proadrenomedullin alone or in combination with big gastrin i as a therapeutic agent
EP2187937A1 (en) * 2007-09-11 2010-05-26 Mondobiotech Laboratories AG Use of the peptide pro-gly-thr-cys-glu-ile-cys-ala-tyr-ala-ala-cys-thr-gly-cys as a therapeutic agent
WO2009046874A1 (en) * 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Therapeutic combination of trh-potentiating peptide and stresscopin
BRPI0921640A2 (pt) * 2008-11-04 2019-09-24 Janssen Pharmaceutica Nv agonistas peptídicos do crhr2 e usos do mesmo
EP2206726A1 (en) * 2009-01-08 2010-07-14 Universite Joseph Fourier Non-invasive tools for detecting vulnerable atherosclerotic plaques
US20110105397A1 (en) * 2009-11-04 2011-05-05 Gengo Peter J Method for treating heart failure with stresscopin-like peptides
WO2013063046A1 (en) 2011-10-24 2013-05-02 Research Development Foundation Methods for increasing insulin secretion by co-stimulation of corticotropin-releasing factor receptors
US20150118287A1 (en) 2012-02-14 2015-04-30 The Regents Of The University Of California Systemic delivery and regulated expression of paracrine genes for cardiovascular diseases and other conditions
JOP20170153A1 (ar) * 2016-07-15 2019-01-30 Lilly Co Eli نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة
KR20190084055A (ko) * 2016-10-20 2019-07-15 코르텐 인코포레이티드 부적응 스트레스 반응에서 기인한 질환의 치료 방법
CN110755434B (zh) * 2018-07-27 2022-03-15 中国医学科学院药物研究所 化合物palosuran防治骨骼肌萎缩等疾病的用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5235036A (en) 1991-05-31 1993-08-10 The Salk Institute For Biological Studies Crf analogs
EP0860501A3 (en) 1994-06-14 1999-05-19 Neurocrine Biosciences, Inc. Corticotropin-releasing factor2 receptors
US5786203A (en) 1994-06-14 1998-07-28 Neurocrine Biosciences, Inc. Isolated nucleic acid encoding corticotropin-releasing factor2 receptors
US5824771A (en) 1994-12-12 1998-10-20 The Salk Institute For Biological Studies Cyclic CRF agonists
US5663292A (en) 1994-12-12 1997-09-02 The Salk Institute For Biological Studies Cyclic CRF analogs
US5660824A (en) 1995-05-24 1997-08-26 Grabstein; Kenneth H. Muscle trophic factor
WO1997000063A2 (en) 1995-06-13 1997-01-03 The Salk Institute For Biological Studies Urocortin peptides
US5869450A (en) 1996-03-06 1999-02-09 The Regents Of The University Of California Anti-inflammatory compositions and method with corticotropin-releasing factor analogs
KR100879232B1 (ko) 2000-08-04 2009-01-20 리서치 디벨럽먼트 파운데이션 우로코르틴 단백질 및 이를 포함하는 약제학적 조성물
US20020082409A1 (en) 2000-10-26 2002-06-27 Hsu Sheau Yu Stresscopins and their uses
US6670140B2 (en) * 2001-03-06 2003-12-30 The Procter & Gamble Company Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors
US7192924B2 (en) 2002-01-16 2007-03-20 The Procter & Gamble Company Corticotropin releasing factor 2 receptor agonists

Also Published As

Publication number Publication date
DE60313845T2 (de) 2008-01-31
JP2005521387A (ja) 2005-07-21
NO20043371L (no) 2004-10-06
US20030148956A1 (en) 2003-08-07
MY140306A (en) 2009-12-31
DE60313845D1 (de) 2007-06-28
CA2470656C (en) 2011-06-28
TW200302276A (en) 2003-08-01
US7897731B2 (en) 2011-03-01
CA2470743A1 (en) 2003-07-31
DK1465921T3 (da) 2006-11-27
DE60318547D1 (de) 2008-02-21
AU2003205197B2 (en) 2006-03-02
KR20040082390A (ko) 2004-09-24
MXPA04006884A (es) 2004-12-06
WO2003062268A2 (en) 2003-07-31
ATE334147T1 (de) 2006-08-15
ATE398632T1 (de) 2008-07-15
CA2470743C (en) 2011-12-13
AU2003237419B2 (en) 2006-04-13
NZ533600A (en) 2007-02-23
NO20043396L (no) 2004-10-06
JP2005525101A (ja) 2005-08-25
US20060025339A1 (en) 2006-02-02
SA03230564B1 (ar) 2006-10-31
IL162431A0 (en) 2005-11-20
PE20030747A1 (es) 2003-10-23
CN100391972C (zh) 2008-06-04
US7192924B2 (en) 2007-03-20
CN1617887A (zh) 2005-05-18
ATE362488T1 (de) 2007-06-15
WO2003062269A3 (en) 2003-11-06
CA2470731C (en) 2011-06-21
SA03230565B1 (ar) 2006-10-31
EP1465923A1 (en) 2004-10-13
EP1724283B1 (en) 2008-06-18
SA03230565A (ar) 2005-12-03
IL196384A0 (en) 2011-07-31
EP1465921A2 (en) 2004-10-13
IL162530A0 (en) 2005-11-20
US6936585B2 (en) 2005-08-30
BR0306878A (pt) 2004-10-26
CY1106133T1 (el) 2011-06-08
EP1724283A2 (en) 2006-11-22
ES2299701T3 (es) 2008-06-01
MA27590A1 (fr) 2005-11-01
WO2003062269A2 (en) 2003-07-31
US7462597B2 (en) 2008-12-09
PT1465923E (pt) 2007-08-06
SI1465921T1 (sl) 2006-10-31
US7632933B2 (en) 2009-12-15
WO2003062277A1 (en) 2003-07-31
EP1465922B1 (en) 2008-01-09
MA27592A1 (fr) 2005-11-01
HK1078095A1 (en) 2006-03-03
SA03230564A (ar) 2005-12-03
IL162529A0 (en) 2005-11-20
US20030148957A1 (en) 2003-08-07
ZA200404995B (en) 2005-06-29
US20100197579A1 (en) 2010-08-05
EP1465923B1 (en) 2007-05-16
ES2287484T3 (es) 2007-12-16
PT1465921E (pt) 2006-12-29
MXPA04006883A (es) 2004-12-06
PE20030849A1 (es) 2003-12-01
MA27591A1 (fr) 2005-11-01
KR100758858B1 (ko) 2007-09-14
RU2294333C2 (ru) 2007-02-27
KR100758857B1 (ko) 2007-09-14
MXPA04006885A (es) 2004-12-06
US7608701B2 (en) 2009-10-27
AR038143A1 (es) 2004-12-29
CN1617886A (zh) 2005-05-18
CN1617885A (zh) 2005-05-18
IL197774A0 (en) 2009-12-24
AR038144A1 (es) 2004-12-29
KR20040082392A (ko) 2004-09-24
BR0306826A (pt) 2005-09-06
AR038142A1 (es) 2004-12-29
EP1724283A3 (en) 2007-04-11
EP1465921B1 (en) 2006-07-26
TW200302278A (en) 2003-08-01
ES2309909T3 (es) 2008-12-16
JP2005522191A (ja) 2005-07-28
WO2003062268A3 (en) 2003-11-27
DE60307044D1 (de) 2006-09-07
US20090124793A1 (en) 2009-05-14
JP4508648B2 (ja) 2010-07-21
CN100475844C (zh) 2009-04-08
RU2004124847A (ru) 2005-04-20
PL371364A1 (en) 2005-06-13
DE60321730D1 (de) 2008-07-31
KR20040082389A (ko) 2004-09-24
TWI300442B (en) 2008-09-01
JP4489434B2 (ja) 2010-06-23
PL373139A1 (en) 2005-08-22
EP1465922A2 (en) 2004-10-13
PE20030974A1 (es) 2003-12-26
NO20043366L (no) 2004-10-06
NZ533599A (en) 2007-03-30
KR100735586B1 (ko) 2007-07-04
CA2470656A1 (en) 2003-07-31
DK1465923T3 (da) 2007-07-02
US7192923B2 (en) 2007-03-20
PL373529A1 (en) 2005-09-05
ES2269976T3 (es) 2007-04-01
ATE383372T1 (de) 2008-01-15
TW200302277A (en) 2003-08-01
JP4508649B2 (ja) 2010-07-21
US20080004435A1 (en) 2008-01-03
US20030148958A1 (en) 2003-08-07
NZ533598A (en) 2007-03-30
CA2470731A1 (en) 2003-07-31
DE60318547T2 (de) 2008-12-24
DE60307044T2 (de) 2007-02-15

Similar Documents

Publication Publication Date Title
BR0306838A (pt) Peptìdeo não-nativo, ácido nucléico isolado, composição farmacêutica e kit para prevenção ou tratamento de uma doença modulada por crf2r
BRPI0413490A (pt) novos compostos
BRPI0409109A (pt) novos compostos
DE60325379D1 (de) Zusammensetzung enthaltend 6-Ä3-(1-adamantyl)-4-methoxyphenylÜ-2-naphthanoesäure zur Behandlung dermatologischer Erkrankungen
BR0305426A (pt) Compostos inibidores de ns5b polimerase de hcv, bem como composição farmacêutica compreendendo os mesmos
IL159960A (en) Indane acetic acid derivatives, pharmaceutical compositions comprising them and uses thereof for the preparation of medicaments
BRPI0614761A2 (pt) proteìnas de fusão de albumina
SE0301009D0 (sv) Novel compounds
NO20050917L (no) Thiomolybdatanaloger og anvendelser derav
BRPI0510664B8 (pt) derivados de fenol e tiofenol 3 ou 4-monosubstituído, composição farmacêutica, combinação e uso dos compostos para tratamento de doenças relacionadas ao h3, incluindo transtornos do sistema nervoso central e transtornos inflamatórios
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
BR0310092A (pt) Combinação de compostos orgânicos
BRPI0407454A (pt) Pirazóis e métodos de preparar e usar os mesmos
WO2007146038A3 (en) Albumin fusion proteins
EA200301232A1 (ru) Новые соединения арилсульфонамида и их применение для лечения ожирения, диабета типа ii и нарушений центральной нервной системы
NO20092274L (no) Ansamycinformuleringer og fremgangsmater for anvendelse derav
DK1465626T3 (da) Farmaceutiske præparater (kit) der omfatter dihydropyridinonforbindelser og et immunregulatorisk (eller et antiinflammatorisk) middel samt anvendelser deraf
NO20054769D0 (no) Substituerte fenylalkansyrer
EA200501710A1 (ru) Замещённые карбоновые кислоты
BRPI0409924A (pt) ácidos amino carboxìlicos substituìdos
DOP2007000053A (es) Compuestos de tetrahidropiridotienopirimidina y métodos para su empleo
BRPI0415872A (pt) ácidos nucleìcos ligando especificamente à grelina bioativa
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
BR0012478A (pt) Derivados de aminotiazóis, sua preparação e composição farmacêuticas contendo os mesmos
BR0315055A (pt) Diamidas de ácido pirimidin-4,6-dicarboxìilco para a inibição seletiva de colagenases

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A(S) 8A ANUIDADE(S).

B08G Application fees: restoration [chapter 8.7 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]